Navigation Links
Semafore's SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
Date:5/30/2009

ncies," said Dr. Chiorean.

This multi-center Phase I study was conducted at: Indiana University Simon Cancer Center, Indianapolis, IN; Arizona Cancer Center, Tucson, AZ; Winship Cancer Institute, Emory University, Atlanta, GA; Scottsdale Clinical Research Institute, Scottsdale, AZ.

About SF1126

SF1126 is the only clinical stage vascular targeted pan-PI3K inhibitor that selectively inhibits all PI3K class I isoforms and other key members of the PI3K superfamily, including mTORC1/2, DNA-PK, PLK-1, CK2, ATM and PIM-1. SF1126 is designed to inhibit both angiogenesis and cell proliferation by targeting and binding to integrins that are expressed on the surface of new tumor vasculature and within the tumor compartment.

In preclinical xenograft models SF1126 has demonstrated broad activity as a single agent; synergy with commonly used chemotherapy agents, targeted agents, and radiation; and has been shown to reverse resistance mediated through the PI3K/PTEN pathway.

About PI3 Kinase

Phosphatidylinositol 3 kinases (PI3K) are involved in one of the major pathways of intracellular signal transduction and are important in controlling cell growth/angiogenesis, differentiation, proliferation and survival/apoptosis. Dysregulation of the PI3 kinase signaling cascades can lead to cancer and aberrant PI3K pathway activity is observed with high frequency in a variety of tumor types. PI3K signaling through its downstream effectors AKT and mTOR is also known to promote tumor cell survival, proliferation, and growth. Dysregulation of PI3K signaling is also thought to contribute resistance to a variety of anticancer therapies. Thus, PI3K is considered a high value target in treating cancer.

About Semafore Pharmaceuticals, Inc.

Semafore is a clinical stage drug discovery and development company focused on small molecule modulato
'/>"/>

SOURCE Semafore Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Semafore Pharmaceuticals Reports Positive Interim Results from a Phase I Study of SF1126, a Targeted Pan-PI3K Inhibitor, in Patients with Advanced Solid Tumors
2. SF1126, Semafores PI3 Kinase Inhibitor, Found to Block Angiogenic Signaling From Both VEGF and Bv8 in Multiple Cell Lines
3. Clinical Data on Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, to be Presented at the 2009 ASCO Meeting
4. ACTOS(R) (pioglitazone HCl) Demonstrates Reduced Risk of Ischemic Cardiovascular Disease in Patients with Type 2 Diabetes
5. Cleveland Clinic Summits to Focus on Cardiovascular Medical Innovation
6. Anthera Announces Completion of Enrollment and Dosing in Phase II Trial of A-002 for the Treatment of Cardiovascular Disease
7. Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
8. Cardiologists Tackle Next Frontier in Cardiovascular Disease
9. Enrollment of Women in Cardiovascular Trials Fails to Meet Current Federal Mandates
10. Synvista Announces New Data Showing Haptoglobin Type Predicts Effectiveness of Tight Glycemic Control on Cardiovascular Outcomes in Patients with Diabetes
11. New Analysis of METEOR Study Demonstrate Effects of AstraZenecas CRESTOR(R) (Rosuvastatin Calcium) on Atherosclerosis in Patients With Two or More Risk Factors for Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... 26, 2015  AbbVie (NYSE: ABBV ... in its neuroscience and oncology development programs have ... American Academy of Neurology annual meeting in ... 18-25. The accepted abstracts feature results from studies ... investigational treatments in AbbVie,s pipeline. Presentations will include ...
(Date:2/26/2015)... , Feb. 26, 2015  IRIDEX Corporation (NASDAQ: ... quarter and full year 2014 financial results after the market ... with the release, the Company will host a conference call ... on Thursday, March 5, 2015 to discuss ... Interested parties may access the live conference call via ...
Breaking Medicine Technology:Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 2AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 3AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 4AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 5AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 6AbbVie's Ongoing Research in Neuroscience and Oncology will be Featured at the 2015 American Academy of Neurology Annual Meeting 7IRIDEX Announces Fourth Quarter and Full Year 2014 Conference Call and Release Date 2
... 23, 2012 Idenix Pharmaceuticals, Inc. (NASDAQ: ... and development of drugs for the treatment of human ... fourth quarter and year ended December 31, 2011 as ... (HCV) development pipeline. Operational HighlightsIDX184 ...
... Psychemedics Corporation (NASDAQ: PMD ) today announced ... December 31, 2011.  The Company also announced an increase in ... of record as of March 5, 2012 to be paid ... consecutive quarterly dividend. The Company,s revenue for the ...
Cached Medicine Technology:Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 2Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 3Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 4Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 5Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 6Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 7Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update 8Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 2Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 3Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 4Psychemedics Corporation Announces a 20% Increase in Revenue and a 34% Increase in Profits for 2011 Year End 5
(Date:2/27/2015)... On February 24 2015, Harper’s Bazaar Magazine ... ,” that details the development of RT001, a form of ... through FDA trials. For those afraid of needles, the idea ... Of course, if the drug ultimately gets FDA approval it ... (see: goo.gl/PQvQwk) , “As the article notes, the size of ...
(Date:2/27/2015)... The winter season is here, and with it comes an ... can be harmful to the home and to one’s health. ... growth with the help of Enviro-Test. Enviro-Test, the mold removal ... ways to prevent mold during the winter months. , Winter ... to thrive. Mold must be removed properly, otherwise there is ...
(Date:2/27/2015)... Florida Hospital North Pinellas is being recognized as a ... In order to receive the award, Florida Hospital North ... With The Guidelines - Stroke Quality Achievement indicators for ... or higher compliance with six of 10 Get With ... initiatives to measure quality of care. , ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 The ... has announced a scholarship for rising freshmen undergraduate students. ... leading periodontist office specializing in many periodontal procedures such ... treatment of gum disease . In honor of ... college scholarship for eligible rising freshmen undergraduate students. ...
(Date:2/27/2015)... FL (PRWEB) February 27, 2015 ... testing company that provides vascular, echocardiogram and NCV ... to be the preferred diagnostic testing provider for ... a coeducational public liberal arts university in Milledgeville, ... the Wimbledon U collegiate division, include ...
Breaking Medicine News(10 mins):Health News:Is Topical Botox the Next Big Thing? 2Health News:Enviro-Test Offers Tips for Winter Mold Prevention 2Health News:Florida Hospital North Pinellas Receives Get With The Guidelines - Stroke Gold Plus Quality Achievement Award 2Health News:Nashville Periodontist Office AIOH Announces 2015 Scholarship 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 2Health News:Georgia College Ensures Student-Athletes Are Heart Smart Team Strong; Teams up with Wimbledon Health Partners to Offer Diagnostic Testing 3
... Mo., Jan. 5 The recent tragic death of Jett ... which he was diagnosed in early childhood. Kawasaki disease is ... the age of five. The disease occurs more often in ... and Korean descent. Although most children diagnosed with Kawasaki recover ...
... Despite a deepening recession, only eight percent of hospital ... year than in 2008 said their institutions would have ... and underinsured, according to a new survey issued today ... overwhelming majority of AHP members surveyed said they will ...
... CHESHIRE, Conn., Jan. 5 Alexion Pharmaceuticals, Inc. (Nasdaq: ... Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present ... San Francisco at 4:30 p.m. local time (7:30 p.m. ... Dr. Bell,s remarks will be available live. You can ...
... Malaria Prevention Campaign has crossed the 50 countries threshold. Over ... broadcasters, non-governmental organizations, youth groups, universities, schools and hospitals. , ... ... and Bite Malaria Prevention Campaign has crossed the 50 countries threshold. ...
... CHICAGO, Jan. 5 Continuing its efforts to,educate, inform, ... a not-,for-profit patient-focused organization, is hosting its 25-minute live ... on Monday,January 12, 2009 at 6:00 PM on Channel ... feature an intimate discussion with Dr. Arthur Dorf,Eye Physician ...
... and REDMOND, Wash., Jan. 5 Microsoft,Health Users Group ... entries for the Microsoft HUG 2009 Innovation Awards. The ... solution partner,recognizes leadership in the use of technology to ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000822/MSFTLOGO ) , ...
Cached Medicine News:Health News:Jett Travolta and Kawasaki Disease: Separating Fact From Fiction 2Health News:AHP Recession Survey of Nonprofit Health Care Officials Finds Almost Half Expect Reduced Giving in 2009, Leading to Cuts in Hospital Construction and Equipment Purchases 2Health News:The Buzz And Bite Malaria Prevention Campaign Is In Use In 50 Countries 2Health News:The Buzz And Bite Malaria Prevention Campaign Is In Use In 50 Countries 3Health News:For Your Eyes Only - How to Choose and Use Your Eye Doctor 2Health News:Microsoft HUG 2009 Innovation Awards Call for Entries Now Open 2Health News:Microsoft HUG 2009 Innovation Awards Call for Entries Now Open 3
... The CMGS-1 Color Mini-Ganzfeld Stimulator is ... can be integrated with your existing LKC ... with other visual electrodiagnostic test systems. ... is the smallest commercial Ganzfeld to meet ...
... the most advanced visual electrodiagnostic system ... of retinal and optic nerve function. ... drives this powerful computer-controlled instrument. With ... pattern stimulation, rapid Ganzfeld flash rate ...
... designed to facilitate an arthrodesis, either by ... interbody cages allowing radicular compression by restoring ... and of the foramina, which in turn ... for major lumbar instabilities.,CC cages are made ...
... SHELLGEL is a sterile nonpyrogenic, transparent ... SHELLGEL contains 12 mg/mL of high molecular ... hyaluronate dissolved in physiological saline. In the ... is 105,000 cps (105 Pa s) at ...
Medicine Products: